**Supplementary Table 1. Calculation formulas of conventional non-invasive models for diagnosing CSPH**

|  |  |
| --- | --- |
| **Score** | **Calculation** |
| AAR | AST/ALT |
| APRI | (AST/ULN)/PLT\*100 |
| CSPH risk score | -0·193-0·359\*ALB+16·456\*INR-0·016\*ALT |
| FIB-4 | Age\*AST/[PLT\*ALT^(1/2)] |
| Fibrosis Index | 8·28-0·01\*PLT-ALB |
| GPR | GGT/PLT |
| King’s score | Age\*AST\*INR/PLT |
| Lok score | -5·56-0·0089\*PLT+1·26\*AST/ALT+5·27\*INR |

ALB, albumin in g/dL; ALT, alanine aminotransferase in U/L; AST, aspartate aminotransferase in U/L; GGT, gamma glutamyl transpeptidase in U/L; PLT, platelet count as \*10^9/L; INR, international normalized ratio; ULN, upper limit of normal; CSPH, clinically significant portal hypertension; AAR, aspartate aminotransferase to alanine aminotransferase ratio; APRI, aspartate aminotransferase to platelet count ratio index; FIB-4, fibrosis index based on four factors; GPR, gamma-glutamyl transpeptidase to platelet count ratio.